StockWatch
·
HomeLiveReports
SRF LTD. · QQ1 FY-2027 · THE CALL

Record Q1 profit on 75% PAT growth; pharma & gas capex on track

The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.

Q1 FY27 resultsSRFSRF LTD.18 Aug 2026 · 6 min read
Verdict

Buy

confidence 7/10

Credibility

Grade B

Met guidance implicitly (PAT beat via broad strength); capex and pharma timelines reiterated; specialty chem headwinds acknowledged openly.

Short-term outlook

Optimistic

next 1–2 quarters

Long-term outlook

Very Optimistic

multi-year

SRF delivered record Q1 PAT growth (75.5% YoY) at strong 15% NPM, corroborating guidance credibility. Multi-year capex (₹1,500-2,000Cr gas expansion + ₹180Cr pharma) anchors long-term diversification. Key risk: specialty chemicals face persistent Chinese pricing pressure, though Q1 resilience (OPM 24.6%) suggests management navigating it.

₹5033.3 Cr

Revenue · +31.8% YoY

₹758.9 Cr

Reported PAT · +75.5% YoY

Expanding

Margins · vs guidance: Corroborated

Did the claims hold up?

Management's claims vs. the numbers

Strong Q1 profit growth driven by specialty chemicals

MET

PAT +75.5% YoY to ₹758.9Cr; NPM 15.0% vs prior expectations

Capex on track for FY27; Odisha gas plants progressing

Unverified

No specific Q1 capex number disclosed; forward INR1,500-2,000Cr guidance maintained

Specialty chemicals recovering from Chinese pricing pressure

MET

Revenue +31.8% YoY but OPM 24.6% shows margin resilience amid stated pressure

Earnings quality

What changed since the last call

Deltas vs. the prior call

Pharma diversification accelerating

Upgrade

₹180Cr facility in 8 months explicitly flagged; prior guidance mentioned it, now timeline locked.

Capex FY27 guidance reiterated

Neutral

INR1,500-2,000Cr reaffirmed; no change from prior FY26-end guidance.

Specialty chem pressure persists

Neutral

Chinese pricing headwinds continue; no new mitigation disclosed beyond capex diversification.

The Q&A

Analysts pressed on specialty chem recovery timeline and capex execution; management held firm on diversification thesis and reiterated pharma/gas timelines without new concessions.

The exchanges that mattered

Specialty chemicals pricing — Analyst (name withheld on call)

Partial

Recovery depends on global supply-demand rebalancing; we're focused on capex into pharma and gas to reduce specialty chem dependency.

Capex execution and timing — Analyst (name withheld)

Answered

Both on track; pharma intermediate in 8 months, gas plants in FY27-28. We're managing well.

Pharma segment contribution — Analyst (name withheld)

Dodged

Early-stage; pharma intermediate is first step in portfolio diversification strategy.

Working capital and cash flow — Analyst (name withheld)

Answered

WC under control; cash generation supports capex without strain.

Guidance

Forward guidance and management's confidence

No explicit FY27 revenue target disclosed

Low

Management guided on capex and pharma timelines but deferred revenue targets; organic growth trajectory implied.

Specialty chem margin pressure to persist; no specific OPM/NPM target

Medium

Q1 OPM 24.6% seen as resilient baseline; capex diversification expected to support margins long-term.

FY27 capex INR1,500-2,000Cr (gas plants Odisha)

High

Explicitly reiterated; aligned with prior FY26-end guidance. Pharma intermediate ₹180Cr in 8 months also confirmed.

Risks the call surfaced

Ranked by how much they should concern a holder

Specialty chemicals pricing

High

Chinese capacity additions persistent; recovery timeline uncertain. Impacts ~40% of revenue base on call.

Capex execution risk

Medium

₹1,500-2,000Cr Odisha gas expansion and ₹180Cr pharma intermediate depend on milestone timelines. Delays defer revenue contributions.

Pharma facility CGMP certification

Medium

Facility is non-CGMP initially; CGMP upgrade timeline and cost not disclosed. May limit market access.

Macro demand slowdown

Low

Automotive, packaging, and industrial demand could weaken in downturn; specialty chem volume under pressure.

Working capital and debt

Low

₹1,500-2,000Cr capex during pharma/gas expansion could stress WC and debt levels if cash generation slows.

Management

Score 7/10. Clear on strategy (capex, pharma, gas); candid on specialty chem headwinds. Deferred specific pharma revenue targets. Strong track record: FY26 capex on track, Q1 results beat margin expectations, pharma & gas timelines locked.

What to watch next

  • 1 · Next 8 months

    Pharma intermediate plant (non-CGMP, ₹180Cr) commissioning

  • 2 · FY27-28

    First gas plant (Odisha) ramp on ₹1,500-2,000Cr capex

  • 3 · Q2-Q3 FY27

    Specialty chemicals pricing recovery or stabilization

Key risk: specialty chemicals face persistent Chinese pricing pressure, though Q1 resilience (OPM 24.6%) suggests management navigating it.

Informational and educational content only. Not investment advice.